Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Measurement of erythrocyte methotrexate polyglutamate levels: ready for clinical use in rheumatoid arthritis?

Danila MI, Hughes LB, Brown EE, Morgan SL, Baggott JE, Arnett DK, Bridges SL Jr.

Curr Rheumatol Rep. 2010 Oct;12(5):342-7. doi: 10.1007/s11926-010-0120-3.

2.

Determinants of erythrocyte methotrexate polyglutamate levels in rheumatoid arthritis.

den Boer E, de Rotte MC, Pluijm SM, Heil SG, Hazes JM, de Jonge R.

J Rheumatol. 2014 Nov;41(11):2167-78. doi: 10.3899/jrheum.131290. Epub 2014 Sep 15.

PMID:
25225283
3.

A short-chain methotrexate polyglutamate as outcome parameter in rheumatoid arthritis patients receiving methotrexate.

Hobl EL, Jilma B, Erlacher L, Duhm B, Mustak M, Bröll H, Högger P, Rizovski B, Mader RM.

Clin Exp Rheumatol. 2012 Mar-Apr;30(2):156-63. Epub 2012 Apr 13.

PMID:
22152098
4.

A population pharmacokinetic model for low-dose methotrexate and its polyglutamated metabolites in red blood cells.

Korell J, Stamp LK, Barclay ML, Dalrymple JM, Drake J, Zhang M, Duffull SB.

Clin Pharmacokinet. 2013 Jun;52(6):475-85. doi: 10.1007/s40262-013-0052-y.

PMID:
23483363
5.

Assessment of intracellular methotrexate and methotrexate-polyglutamate metabolite concentrations in erythrocytes by ultrafast matrix-assisted laser desorption/ionization triple quadrupole tandem mass spectrometry.

Meesters RJ, den Boer E, de Jonge R, Lindemans J, Luider TM.

Rapid Commun Mass Spectrom. 2011 Oct 30;25(20):3063-70. doi: 10.1002/rcm.5202.

PMID:
21953961
6.

Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis.

Angelis-Stoforidis P, Vajda FJ, Christophidis N.

Clin Exp Rheumatol. 1999 May-Jun;17(3):313-20.

PMID:
10410264
7.

Assessment of the relationship between methotrexate polyglutamates in red blood cells and clinical response in patients commencing methotrexate for rheumatoid arthritis.

Pan S, Stamp LK, Duffull SB, Barclay ML, Dalrymple JM, Drake J, Zhang M, Korell J.

Clin Pharmacokinet. 2014 Dec;53(12):1161-70. doi: 10.1007/s40262-014-0179-5.

PMID:
25204405
8.

Determination of erythrocyte methotrexate polyglutamates by liquid chromatography/tandem mass spectrometry after low-dose methotrexate therapy in Chinese patients with rheumatoid arthritis.

Mo X, Wen Y, Ren B, Chen J, Xu C, Wang X, Huang M, Chen X.

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Oct 15;907:41-8. doi: 10.1016/j.jchromb.2012.08.032. Epub 2012 Sep 1.

PMID:
22999476
9.

Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment.

Stamp LK, O'Donnell JL, Chapman PT, Zhang M, Frampton C, James J, Barclay ML.

Arthritis Rheum. 2009 Aug;60(8):2248-56. doi: 10.1002/art.24653.

10.

Prediction of the therapeutic response to methotrexate at 24 weeks by methotrexate-polyglutamates concentration in erythrocytes at 8 weeks in patients with rheumatoid arthritis.

Murosaki T, Nagatani K, Sato T, Akiyama Y, Ushijima K, Lefor AK, Fujimura A, Minota S.

Mod Rheumatol. 2017 May;27(3):411-416. doi: 10.1080/14397595.2016.1208137. Epub 2016 Jul 20.

PMID:
27435295
11.

High Methotrexate Triglutamate Level Is an Independent Predictor of Adverse Effects in Asian Indian Rheumatoid Arthritis Patients-A Preliminary Study.

Sandhu A, Dhir V, Bhatnagar A, Dhawan V, Kaur J, Sood A, Naidu S, Ahmad S, Varma N, Sharma A, Sharma S.

Ther Drug Monit. 2017 Apr;39(2):157-163. doi: 10.1097/FTD.0000000000000375.

PMID:
28107255
12.

Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy.

Stamp LK, O'Donnell JL, Chapman PT, Zhang M, James J, Frampton C, Barclay ML.

Arthritis Rheum. 2010 Feb;62(2):359-68. doi: 10.1002/art.27201.

13.

Effect of methotrexate use and erythrocyte methotrexate polyglutamate on glycosylated hemoglobin in rheumatoid arthritis.

de Rotte MC, de Jong PH, den Boer E, Pluijm SM, Özcan B, Weel AE, Lindemans J, Hazes JM, de Jonge R.

Arthritis Rheumatol. 2014 Aug;66(8):2026-36. doi: 10.1002/art.38652.

14.

Adenosine and methotrexate polyglutamate concentrations in patients with juvenile arthritis.

Dolezalová P, Krijt J, Chládek J, Nemcová D, Hoza J.

Rheumatology (Oxford). 2005 Jan;44(1):74-9. Epub 2004 Sep 28.

PMID:
15454631
15.

HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis.

Dervieux T, Orentas Lein D, Marcelletti J, Pischel K, Smith K, Walsh M, Richerson R.

Clin Chem. 2003 Oct;49(10):1632-41.

16.

Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis.

Dervieux T, Zablocki R, Kremer J.

Rheumatology (Oxford). 2010 Dec;49(12):2337-45. doi: 10.1093/rheumatology/keq216. Epub 2010 Aug 16.

PMID:
20713496
18.

Preliminary study to identify the predictive factors for the response to methotrexate therapy in patients with rheumatoid arthritis.

Inoue S, Hashiguchi M, Takagi K, Kawai S, Mochizuki M.

Yakugaku Zasshi. 2009 Jul;129(7):843-9.

19.

Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis.

Stamp LK, Barclay ML, O'Donnell JL, Zhang M, Drake J, Frampton C, Chapman PT.

J Rheumatol. 2011 Dec;38(12):2540-7. doi: 10.3899/jrheum.110481. Epub 2011 Oct 1.

PMID:
21965639
20.

The influence of methotrexate on the gene expression of the pro-inflammatory cytokine IL-12A in the therapy of rheumatoid arthritis.

Hobl EL, Mader RM, Erlacher L, Duhm B, Mustak M, Bröll H, Högger P, Kalipciyan M, Jilma B.

Clin Exp Rheumatol. 2011 Nov-Dec;29(6):963-9. Epub 2011 Dec 22.

PMID:
22133036

Supplemental Content

Support Center